You are here

  • Home
  • Archive
  • Volume 79, Issue Suppl 1
  • OP0021 OLOKIZUMAB, MONOCLONAL ANTIBODY AGAINST IL6, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS INADEQUATELY CONTROLLED BY METHOTREXATE: EFFICACY AND SAFETY RESULTS OF PHASE III CREDO-1 STUDY

Article metrics

Article menu
Download PDFPDF
Scientific Abstracts
Oral Presentations
Biological DMARDs in RA I
OP0021 OLOKIZUMAB, MONOCLONAL ANTIBODY AGAINST IL6, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS INADEQUATELY CONTROLLED BY METHOTREXATE: EFFICACY AND SAFETY RESULTS OF PHASE III CREDO-1 STUDY

 

Online download statistics by month:

Online download statistics by month: June 2020 to March 2024

AbstractFullPdf
Jun 2020238033
Jul 20204204
Aug 20205603
Sep 20203801
Oct 20204202
Nov 20209005
Dec 20207408
Jan 20217503
Feb 20218300
Mar 202112107
Apr 20215302
May 20212402
Jun 2021107
Jul 2021203
Aug 2021005
Sep 2021201
Oct 20216202
Nov 20213402
Dec 20211400
Jan 20221601
Feb 20222001
Mar 20223400
Apr 20221802
May 20224200
Jun 20221900
Jul 20222900
Aug 20226601
Sep 202222701
Oct 20222500
Nov 20226503
Dec 20223400
Jan 20237000
Feb 20231700
Mar 20232702
Apr 20231301
May 20231100
Jun 20231000
Jul 2023400
Aug 20231100
Sep 202312900
Oct 20233202
Nov 202318402
Dec 2023600
Jan 20241701
Feb 2024600
Mar 20243000
Total22130107